Blog

Stay Current on all things IP by subscribing to our blog

Harness IP takes pride in our collective knowledge of intellectual property law and how it affects businesses and organizations across a range of industries. We also enjoy keeping up with the latest decisions from the prominent venues that affect IP law, including the Federal Circuit, the U.S. Supreme Court, and the PTAB. Our goal is to distill this knowledge into practical guidance that in-house counsel and others can use. We invite you to join our audience and enrich the discussion whenever possible.

August 8, 2025

“Navigating Patent Term Adjustment and Patent Term Extension: Recent Court Rulings and Their Impact on Obviousness-Type Double Patenting,” The National Law Review

More
July 7, 2025

U.S. Chemical & Life Science Patents Q2 Newsletter

More
June 30, 2025

5 Federal Circuit Patent Cases You Need To Know

More
June 26, 2025

Enablement, Anticipation, and Claim Strategy: Rethinking Biotech Patent Drafting Post-Agilent

More
June 23, 2025

Six Actions to Take to Ensure Your Trade Secret Stays Secret

More
June 23, 2025

Cannabis And Trademarks: Protecting Against Infringement

More

shutterstock court with gavel | Intellectual Property Law Firm | Harness IP

September 29, 2016

Let the Punishment Fit the Crime

By: Bryan K. Wheelock, Principal

September 23, 2016

Function Claim Language Shows That Claims are Directed to Abstract Idea, Not a Concrete Technical Innovation

By: Bryan K. Wheelock, Principal

Harness IP patent Attorneys Detroit St. Louis Dallas Washington, DC

September 23, 2016

Stripped of Excess Verbiage, Claim Directed to Streaming Out-of-Region Media to Cell Phones in an Abstract Idea

By: Bryan K. Wheelock, Principal

September 23, 2016

Structural Element Does Not Make Method Claims Indefinite

By: Bryan K. Wheelock, Principal

September 22, 2016

It was Error Not to Consider Secondary Considerations, But They Wouldn’t Have Made a Difference

By: Bryan K. Wheelock, Principal

September 21, 2016

Federal Circuit Remands Issue of Enhanced Damages for Determination Whether this was an Egregious Case of Misconduct Beyond Typical Infringement

By: Bryan K. Wheelock, Principal

shutterstock DNA | Intellectual Property Law Firm | Harness IP

September 20, 2016

Inherent Disclosure is Sufficient to Support a Priority Claim

By: Bryan K. Wheelock, Principal

8007204 2 | Intellectual Property Law Firm | Harness IP

September 17, 2016

Backgrounds — The Less Said the Better

By: Bryan K. Wheelock, Principal

September 16, 2016

Substantial Evidence Supported Infringement of Limitations That Did Not Need Construction

By: Bryan K. Wheelock, Principal

September 16, 2016

PTAB Decision to Institute Despite Alleged § 315 Time Bar is Not Reviewable

By: Bryan K. Wheelock, Principal

September 13, 2016

Read Our Lips: Not Everything is Abstract

By: Bryan K. Wheelock, Principal

BioPharma banner 10 26 17 | Intellectual Property Law Firm | Harness IP

September 8, 2016

BioPharma Patents Quick Tips & News – November/December 2013 – Throwback Edition

By: Leanne M. Rakers, Principal

IPOM image | Intellectual Property Law Firm | Harness IP

September 6, 2016

The Intellectual Property Owner’s Manual

By: Bryan K. Wheelock, Principal

shutterstock 156673100 | Intellectual Property Law Firm | Harness IP

September 1, 2016

PTAB Reversed Based on Non-Analogous Art Theory

By:

shutterstock 240614686 small e1453910269364 | Intellectual Property Law Firm | Harness IP

August 30, 2016

Federal Circuit Demonstrates Willingness to Rein in PTAB’s Onerous Idle Free Rules Regarding Claim Amendments

By: Douglas A. Robinson, Principal

Harness IP Intellectual Property Lawyers

August 30, 2016

Claim Narrowed by Specification is Saved from Indefiniteness but too Narrow to be Infringed

By: Bryan K. Wheelock, Principal

August 30, 2016

Compliance with PTAB’s Requirements for Motion to Amend Arbitrary and Capricious?

By: Bryan K. Wheelock, Principal

August 24, 2016

45 Months of Inter Partes Review – By the Numbers

By: Matthew L. Cutler, Principal

August 16, 2016

“Substantial Evidence” Hurdle is Substantially Difficult to Overcome

By: Douglas A. Robinson, Principal

patent law pharma law biopharma patents

August 15, 2016

Broad Original Claims Prevent Invalidity for Lack of Adequate Written Description

By: Bryan K. Wheelock, Principal